香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 茲載列上海復星醫藥（ 集團 ）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 公司藥品新納入國家醫保目錄及商保創新藥目錄的提示性公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （ 於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 证券代码：600196 股票简称：复星医药 编号：临 2025-192 上海复星医药（集团）股份有限公司 关于公司药品新纳入国家医保目录 董事長 陳玉卿 中國，上海 2025年12月7日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生、王可心先生及劉毅先生；本公 司 之 ...

人民财讯12月7日电，复星医药（600196）12月7日公告，根据12月7日国家医保局、人社部发布的《国家基本 医疗保险、生育保险和工伤保险药品目录(2025年)》(简称"2025年国家医保目录")以及首次发布的《商业健康 保险创新药品目录(2025年)》(简称"商保创新药目录")，公司及控股子公司/单位多款已上市产品获首次纳入或 涉及备注信息调整。公司芦沃美替尼片等药品新纳入国家医保目录，阿基仑赛注射液新纳入商保创新药目 录。 | 情形 | 药品名称 | 中国境内* | 中国境内 * | | --- | --- | --- | --- | | | | 商品名 | 首次获批上市时间 | | 2025 年国家医保目录 | | | | | 新纳入 | 芦沃美替尼片 | 复迈宁 | 2025年5月 | | 枸橡酸伏维西利胶囊 | | 复要宁 | 2025年5月 | | 吡仑帕奈口服混悬液 | | 奥捷宁 | 2025年9月 | | 盐酸替那帕诺片 | | 万缇乐 | 2025年2月 | | 普托马尼片 | | 普瑞尼 | 2024 年 12 月 | | 备注信息调整 (新增活应症) | 盐酸凯普拉生片 | 倍稳 | ...

1 情形 药品名称 中国境内 1 商品名 中国境内 1 首次获批上市时间 2025 年国家医保目录 新纳入 芦沃美替尼片 复迈宁 2025 年 5 月 枸橼酸伏维西利胶囊 复妥宁 2025 年 5 月 吡仑帕奈口服混悬液 奥捷宁 2025 年 9 月 盐酸替那帕诺片 万缇乐 2025 年 2 月 普托马尼片 普瑞尼 2024 年 12 月 备注信息调整 （新增适应症） 盐酸凯普拉生片 倍稳 2023 年 2 月 备注信息调整 （适应症表述更新） 拓培非格司亭注射液 珮金 2023 年 6 月 商保创新药目录 新纳入 阿基仑赛注射液 奕凯达 2021 年 6 月 一、新获纳入或涉及备注信息调整的主要品种 二、对上市公司的影响及风险提示 2025 年国家医保目录、商保创新药目录将于 2026 年 1 月 1 日起执行。其中， 2025 年国家医保目录的具体医保支付标准、医保报销细则、谈判药品的协议有 效期等信息，须以国家医疗保障局等相关政府部门公示信息为准。 证券代码：600196 股票简称：复星医药 编号：临 2025-192 上海复星医药（集团）股份有限公司 关于公司药品新纳入国家医保目录 及商保创新药目录的 ...

复星医药公告称，根据2025年12月7日发布的2025年国家医保目录和商保创新药目录，集团多款已上市 产品获首次纳入或涉及备注信息调整，如芦沃美替尼片、阿基仑赛注射液等。两目录将于2026年1月1日 起执行。相关药品2024年度及2025年前三季度销售额合计分别约为4.01亿元、8.92亿元，分别占同期集 团营收的0.98%、3.04%。本次纳入预计对集团后续业绩产生积极影响，但具体影响尚无法确定。 ...

Core Viewpoint - The acceptance of the marketing registration application for HLX14, a biosimilar of denosumab by Fosun Pharma, marks a significant advancement in providing new treatment options for osteoporosis in China, following approvals in Europe and the US [1][3]. Group 1: Product Development and Market Position - Fosun Pharma's subsidiary, Fuhong Hanlin, has submitted a marketing registration application for HLX14, a biosimilar of denosumab, aimed at treating osteoporosis in postmenopausal women and men, as well as glucocorticoid-induced osteoporosis [1]. - The original denosumab, developed by Amgen, has generated over $7 billion in global sales, with a significant presence in the domestic market where it was approved around 2020 and included in the medical insurance directory [3]. - In 2024, the sales of denosumab in the domestic hospital market exceeded 1.8 billion yuan, reflecting a year-on-year growth rate of 57%, and in the first half of 2025, sales surpassed 1.4 billion yuan, with a growth rate of 79.05% [3]. Group 2: Competitive Landscape - The expiration of the original drug's patent has intensified competition in the domestic biosimilar market, with four companies, including Taikang Biopharma and Qilu Pharmaceutical, having received approvals for denosumab biosimilars [5]. - Several other companies, such as Maitaiabo and Haosen Pharmaceutical, are actively advancing their clinical trials for denosumab biosimilars, indicating a clearer competitive landscape in this sector [5]. Group 3: Investment and Future Outlook - As of October this year, Fosun Pharma has invested approximately 320 million yuan in the development of the denosumab injection product, and successful approval of this application could open new growth pathways for the company [11]. - The entry of more biosimilars and improved new drugs in the market is expected to enhance accessibility, treatment options, and long-term management for patients, ultimately benefiting a larger patient population [11].

近日，复星健康与Fakeeh Care Group在沙特吉达正式签署战略合作备忘录。双方围绕专科建设与学术交流、IT与数字化医院解决方案、预防医学与可穿戴设 备、干细胞与再生医学四大核心方向达成战略合作探索意向，为"一带一路"倡议下中沙医疗健康合作注入新活力，也为沙特"2030 愿景"医疗板块升级添砖 加瓦。 近日，复星健康董事长兼首席执行官胡航，复星健康联席总裁、首席战略官沈赟，复星健康副总裁、佛山复星禅诚医院院长赵晓东等领导团队，受邀前往沙 特阿拉伯，对当地领先的私营医疗健康集团Fakeeh Care Group进行实地考察与深度交流。 复星健康领导一行参观了该集团位于吉达的旗舰医院，双方围绕医院规划、学科运营和服务质量等议题展开深入探讨。复星健康董事长兼首席执行官胡航对 Fakeeh Care Group医院体系化的管理、先进设施和高标准服务表示赞赏，期待双方团队紧密协作，推动合作项目扎实落地。Fakeeh Care Group吉达旗舰医院 首席执行官Sohail Bajammal博士表示，沙特医疗市场需求广阔，期待引入复星健康在中国市场的经验与创新模式，共同促进项目在沙成功实施。 随后，在复星健康董事 ...

证券代码：600196 证券简称：复星医药 公告编号：临2025-190 上海复星医药（集团）股份有限公司关于 2025年A股股票期权激励计划首次授予结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性、完整性承担法律责任。 重要内容提示： ●A股期权首次授予登记日：2025年12月2日 ●A股期权首次授予登记数量：4,446,400份 根据《上海复星医药（集团）股份有限公司2025年A股股票期权激励计划》（以下简称"2025年A股期权 计划"或"本次激励计划"）及上海复星医药（集团）股份有限公司（以下简称"本公司"）2025年第一次 临时股东会的授权，本次激励计划首次授予及登记工作已完成，现将相关事项公告如下： 一、本次激励计划首次授予情况 2025年11月4日，本公司第十届董事会第十四次会议审议通过关于2025年A股期权计划首次授予相关事 项的议案，董事会认为本次激励计划首次授予的条件已经成就，同意以2025年11月4日作为首次授予 日、向共计195名首次授予激励对象授予合计4,535,100份A股期权，并办理该授予所需的相关事宜。该 议案 ...

Core Viewpoint - Fosun Pharma has received approval from the National Medical Products Administration for clinical trials of FXS887 tablets for advanced malignant solid tumors [1] Group 1 - Fosun Pharma's subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., is set to conduct Phase I clinical trials of FXS887 in China once conditions are met [1]

Group 1 - Dongfang Electric announced that three executives plan to reduce their holdings by a total of no more than 30,000 shares due to personal financial needs [1] - Yahu Pharmaceutical's APL-1401 clinical trial data was presented at the 19th European Colorectal Congress, indicating progress in treating moderate to severe ulcerative colitis [1] - Guizhou Bai Ling's actual controller is under investigation by the China Securities Regulatory Commission for insider trading and information disclosure violations [3] Group 2 - Bairen Medical's ePTFE pericardial membrane product has been approved for registration, ending the reliance on imports for this product in the domestic market [4] - Qianxin received approval for a total of 2 billion yuan in technology innovation bonds, with plans to issue medium-term notes and short-term financing bonds [6] - Tengjing Technology's shareholder plans to reduce holdings by no more than 1.96% of the company's shares [7] Group 3 - Yuntianhua's subsidiary is required to pay 386 million yuan in overdue taxes and penalties, which will impact the company's net profit for 2025 [8] - Jianyou Pharmaceutical's propofol emulsion injection has received FDA approval in the United States [9] - Suzhou Gaoxin successfully acquired land use rights for a residential project for 360 million yuan [9] Group 4 - Chalco International's subsidiary won a bid for a 3.03 billion yuan electrolytic aluminum project [11] - Tai Long Pharmaceutical's stock will continue to be suspended due to potential changes in control as the major shareholder is planning a share transfer [12] - Qianli Technology reported a 63.44% year-on-year increase in automobile sales for November, although new energy vehicle sales decreased by 43.98% [13] Group 5 - Fosun Pharma's innovative drug FXS0887 has received approval for a Phase I clinical trial for advanced malignant solid tumors [14] - Guoen Co. has obtained approval for a project to produce 20,000 square meters of aviation-grade acrylic glass, with a total investment of 560 million yuan [15] - Guofa Co.'s chairman resigned due to personal reasons [17] Group 6 - Shanghai Construction won a bid for a state-owned construction land use right for 264 million yuan [18] - Weixin Kang's subsidiary received approval for a clinical trial of lidocaine cream for local anesthesia [20] - Sanxing Medical's subsidiary is a candidate for a 152 million yuan transformer procurement project for the State Grid [20] Group 7 - People's Daily announced the resignation of its president due to work changes, while retaining other leadership roles [21] - Beibu Gulf Port reported a 0.29% year-on-year increase in cargo throughput for November [22] - Chongqing Construction won three engineering projects with a total value of approximately 2.773 billion yuan [23] Group 8 - Xingyu Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange [24] - Huajian Group signed a design contract worth 160 million yuan for a comprehensive project [25] - Wankai New Materials plans to invest 350 million yuan in a technical transformation project for producing 100,000 tons of adipic acid [26] Group 9 - Kaipuyun received a government subsidy of 18 million yuan, which is 87.43% of its net profit for the last audited fiscal year [28] - Ningbo Port expects a 10.8% year-on-year increase in container throughput for November [30] - An Cai High-Tech plans to invest 498 million yuan to upgrade its photovoltaic glass production line [32] Group 10 - Shunhao Co. stated that its existing business has not generated synergies with the rail business, which faces various risks [34] - Yihualu plans to publicly transfer 35% of its stake in Liaoyun Company [35] - ST Wanfang's shareholder plans to reduce holdings by no more than 3% of the company's shares [36] Group 11 - Youyou Food's shareholder plans to reduce holdings by no more than 110,000 shares [38] - Hengtong Optic-Electric's incentive fund has spent 49.98 million yuan to purchase company shares [41] - Zoli Pharmaceutical plans to issue convertible bonds to raise no more than 1.556 billion yuan for various projects [42]

Core Viewpoint - Fosun Pharma has received approval from the National Medical Products Administration for clinical trials of FXS0887, an innovative oral small molecule drug aimed at treating advanced malignant solid tumors [1] Group 1: Clinical Trial Approval - Fosun Pharma's subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., has been authorized to conduct Phase I clinical trials of FXS0887 in China once conditions are met [1] - The drug targets advanced malignant solid tumors and specifically inhibits ATR kinase activity, which is involved in cell cycle regulation and DNA damage repair pathways [1] Group 2: Drug Development and Efficacy - FXS0887 has shown promising anti-tumor activity in various tumor models during preclinical studies, with a low risk of off-target effects and good safety profile [1] - As of October 2025, the cumulative R&D investment for FXS0887 is approximately RMB 44 million (unaudited) [1] Group 3: Market Context - As of the announcement date (December 3, 2025), there are no approved small molecule inhibitors targeting the same pathway as FXS0887, either as monotherapy or in combination therapy, globally [1]